GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

partnership

08/18/2025 - 09:05 AM

Until today, Ozempic^®has not been available to eligible self-paying patients at this price

SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic^® (semaglutide) and Wegovy^® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic^® has been made available to patients at this self-pay price.

“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” said Wendy Barnes, President and Chief Executive Officer of GoodRx. “By partnering with Novo Nordisk, we’re taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It’s a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.”

In the last year, almost 17 million people came to GoodRx looking for savings and information on GLP-1 medications, a 22% increase from the previous year. Now, GoodRx is poised to more effectively meet this growing demand by leveraging the extensive reach and scale of its trusted platform to deliver savings directly to patients who need them. This collaboration represents a significant milestone in improving access and affordability of these important, authentic, FDA-approved medications.

“Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,” said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. “This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic^® self-pay offer for type 2 diabetes patients at an unprecedented price.”

Healthcare professionals are increasingly prescribing these groundbreaking medications to support patients diagnosed with type 2 diabetes or obesity—yet insurance coverage remains a challenge for many seeking treatment, especially those seeking obesity medications. For example, GoodRx research shows 19 million people lack coverage for any GLP-1s prescribed for weight loss. By filling the gaps in insurance coverage, GoodRx is playing a critical role in reducing friction in the system and helping accelerate speed to therapy so consumers can benefit from these critical treatments.

Starting today, eligible patients can use GoodRx to self-pay for Ozempic^® and Wegovy^® pens for $499-per-month at over 70,000 retail pharmacies nationwide.

To learn more, visit: GoodRx.com/Ozempic or GoodRx.com/Wegovy

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk and other pharmaceutical manufacturers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.